AOD-9604 vs Survodutide
Both AOD-9604 and Survodutide are used for weight-loss. Here's how their evidence, dosing, and regulatory status actually compare.
AOD-9604
Evidence C+Anti-Obesity Drug 9604
A modified fragment of human growth hormone (hGH 176-191) that stimulates fat breakdown without the growth-promoting or diabetogenic effects of full HGH.
View full AOD-9604 profile →Survodutide
Evidence ASurvodutide (BI 456906)
A dual GLP-1 / glucagon receptor agonist with strong Phase 2 weight-loss and MASH data. Resolution of MASH in 83% of participants at the highest dose at week 48.
View full Survodutide profile →Side-by-Side
| Attribute | AOD-9604 | Survodutide |
|---|---|---|
| Evidence Grade | C+ | A |
| FDA Status | Not FDA-approved — Category 1 (compounding allowed) | Not FDA-approved — Phase 3 trials for obesity and MASH |
| Typical Dose | 250–500 mcg daily (subcutaneous) | Trial range: 0.6–6 mg weekly (subcutaneous) |
| Clinics Indexed | 134 | 6 |
| Categories | weight-loss, fat-loss | weight-loss, metabolic |
Key reported benefits — AOD-9604
- ✓Fat metabolism
- ✓No HGH side effects
- ✓Cartilage repair potential
Key reported benefits — Survodutide
- ✓Weight loss
- ✓MASH resolution
- ✓Glucose control
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.